Blood biomarkers could replace invasive biopsies for colorectal cancer monitoring

NCT ID NCT07754513

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study investigates whether tiny particles shed by tumors into the blood, called extracellular vesicles, can serve as a non-invasive biomarker for metastatic colorectal cancer. Researchers will analyze blood samples from 290 patients at different treatment stages to see if these vesicles' RNA and protein signatures can predict treatment response and monitor disease progression. The goal is to develop a simple blood test that could guide personalized treatment decisions without the need for repeated tissue biopsies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Blood sample collection for extracellular vesicle biomarker analysis
What this could lead to
If successful, this could lead to a simple blood test to monitor colorectal cancer progression and personalize treatment without invasive biopsies.
What could go wrong
This is an observational study, so it won't directly test a treatment. The biomarkers may not prove reliable enough for clinical use, and results may not generalize beyond the specific patient group studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.